NYC Firm Synchron Beats Elon Musk to Brain-Computer FDA Trials

Updated: Dec 29, 2021

Sharing this Article from Nasdaq


If you thought mind control was only for sci-fi characters like X-Men's Professor Xavier, think again. A bioelectronics company will soon launch U.S. clinical trials of brain implants that allow patients with conditions like paralysis to control digital devices...with their minds.


If you thought mind control was only for sci-fi characters like X-Men's Professor Xavier, think again. A bioelectronics company will soon launch U.S. clinical trials of brain implants that allow patients with conditions like paralysis to control digital devices...with their minds.

New York City-based Synchron said Wednesday that the U.S. Food and Drug Administration cleared its device for testing in human patients, putting the futuristic technology on the cusp of heading to market. Synchron beat out scrambling competitors to reach this stage — namely Elon Musk's Neuralink.


Giving Patients Mind Control

Synchron will plant a device smaller than a matchstick that it calls Stentrode into the brains of six paralyzed patients later this year. Stentrode will allow patients to control digital devices (like moving a computer cursor) with their thoughts by transmitting to a second implant in the chest, which then signals to digital devices. The potential already has investors salivating: Read the Full Article


3 views0 comments